BIM
SNDX icon

BlackRock Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

BlackRock Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$259K Hold
36,068
– – ﹤0.01% 3195
2016
Q3 		$547K Hold
36,068
– – ﹤0.01% 3006
2016
Q2 		$355K Buy
36,068
+17,982
+99% +$247K ﹤0.01% 3189
2016
Q1 		$241K Buy
+18,086
New +$227K ﹤0.01% 3123

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock Investment Management's SNDX Position: Q4 2016 in Review

BlackRock Investment Management held its Syndax Pharmaceuticals (SNDX) position steady in Q4 2016 at 36,068 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

BlackRock Investment Management first reported a position in SNDX in Q1 2016 and has held it in 4 quarters since. The position peaked at $547K in Q3 2016. 57 funds tracked by Wall St. Rank hold SNDX as of Q4 2016.

  • BlackRock Investment Management held 36,068 shares of Syndax Pharmaceuticals worth $259K as of Q4 2016.
  • BlackRock Investment Management left its Syndax Pharmaceuticals share count unchanged in Q4 2016.
  • Syndax Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3195 holding.
  • BlackRock Investment Management first reported a position in Syndax Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Investment Management's Syndax Pharmaceuticals position peaked at $547K in Q3 2016.
  • 57 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.